# Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

> **NCT03938792** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 189 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** PF-06741086

## Key facts

- **NCT ID:** NCT03938792
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-09
- **Primary completion:** 2025-04-29
- **Final completion:** 2025-04-29
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03938792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03938792, "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03938792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*